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Abstract
Iron is an essential nutrient in several biological processes such as oxygen transport, DNA replication and erythropoiesis.
Plasma iron normally circulates bound to transferrin. In iron overload disorders, however, iron concentrations exceed
transferrin binding capacity and iron appears complexed with low molecular weight molecules, known as non-transferrin-
bound iron (NTBI). NTBI is responsible for the toxicity associated with iron-overload pathologies but the mechanisms
leading to NTBI uptake are not fully understood. Here we show for the first time that T lymphocytes are able to take up and
accumulate NTBI in a manner that resembles that of hepatocytes. Moreover, we show that both hepatocytes and T
lymphocytes take up the oligomeric Fe3Cit3 preferentially to other iron-citrate species, suggesting the existence of a
selective NTBI carrier. These results provide a tool for the identification of the still elusive ferric-citrate cellular carrier and
may also open a new pathway towards the design of more efficient iron chelators for the treatment of iron overload
disorders.
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Introduction
Iron, the most abundant transition metal in mammalian
systems, is essential for metabolic processes, including molecular
oxygen transport and DNA synthesis. Under normal conditions,
iron circulates in the plasma bound to transferrin and this
constitutes the major iron source for iron-avid processes, such as
erythropoiesis [1]. Circulating iron which is not bound to
transferrin, heme or ferritin (here designated as non-transferrin-
bound iron - NTBI) becomes important in iron overload disorders,
in which plasma iron is present in excess of transferrin-binding
capacity [2,3]. In contrast to transferrin-bound iron, NTBI is
avidly taken up by the liver [4,5]. The uptake of NTBI by
hepatocytes is viewed as a clearance mechanism of potentially
toxic circulating iron that could otherwise, due to its involvement
in the formation of free oxygen radicals [2], cause damage to other
cell types. However, even the robust hepatocyte has a threshold
beyond which iron accumulation becomes toxic, leading to the
development of liver pathologies such as fibrosis, cirrhosis and
hepatocarcinoma. These conditions are hallmarks of iron overload
disorders, including beta-thalassemia and hereditary hemochro-
matosis. Besides hepatocytes, a variety of other cell types have also
been shown to take up NTBI [6]. The specific iron uptake kinetics
displayed by distinct cell types [7–9], together with the observation
of distinct patterns of affected organs in different iron overload
diseases [10], all suggest that either the different cell types may
differ in the expression of the same NTBI-carrier molecule(s) or
that they possess different uptake systems capable of discriminating
between the various circulating NTBI species. Until now little was
known about the capacity of T lymphocytes to take up NTBI. As
one of the major cellular components of peripheral blood, T
lymphocytes can be exposed to circulating NTBI and have been
for a long time proposed to act as a first physiological barrier
against iron-mediated toxicity in situations of systemic iron
overload (reviewed in Porto and De Sousa [11]). The first
evidence suggesting a role for T lymphocytes in the modulation of
NTBI deposition came from the demonstration of liver iron
overload in mice deficient in CD8+- and total T lymphocytes [12–
14]. In addition, a negative correlation has been consistently found
between total body iron stores and CD8+ lymphocytes in the
peripheral blood and was also documented in liver biopsies from
HFE-hemochromatosis patients [15,16], supporting their role in
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the protection against iron accumulation. In the present study we
provide, for the first time, evidence demonstrating that T
lymphocytes are able to take up and accumulate NTBI and that,
like hepatocytes, selectively uptake a unique oligomeric ferric
citrate species in conditions mimicking those observed during iron
overload disorders, suggesting the existence of a selective NTBI
carrier.
Methods
Ethics Statement
Animal care and procedures were in accordance with institu-
tional guidelines. This study and all conducted experiments were
approved by the IBMC.INEB Animal Ethics Committee, in
accordance with the Portuguese Veterinary Director General
guidelines. Peripheral Blood Mononuclear Cells and peripheral
blood were obtained from patients at Santo Anto´nio General
Hospital (Porto, Portugal), who gave their written informed
consent to participate in this study, which was approved by the
Santo Anto´nio Hospital Ethical Committee.
Reagents and antibodies
55FeCl3,
125I-Transferrin and 14C-labeled citric acid were
purchased from Perkin Elmer; microbead-conjugated anti-CD3,
anti-CD4 and anti-CD8 antibodies were purchased from Miltenyi
Biotec; sucrose and Dynasore were purchased from Sigma
Chemical Co; siRNAs were purchased from Eurogentec.
Isolation of human peripheral blood cells
Peripheral Blood Mononuclear Cells (PBMCs) were obtained
from apparently healthy volunteer blood donors, randomly
recruited at Santo Anto´nio Hospital Blood Bank (Porto, Portugal).
Cells were isolated by gradient centrifugation over Lymphoprep
(Nycomed). After lysis of erythrocytes, cells were resuspended in
RPMI (GibcoBRL) supplemented with 10% fetal calf serum (FCS;
GibcoBRL) and plated. CD3+, CD4+ and CD8+ cells were
purified from PBMCs using magnetic-activated cell sorting
(MACS), after incubation with specific microbead- conjugated
antibodies, according to manufacturer’s instructions.
Isolation of plasma from a hereditary hemochromatosis
patient
Peripheral blood was collected from an iron-overloaded
hereditary hemochromatosis patient at the time of a scheduled
phlebotomy. Nine ml of blood were transferred to blood collection
tubes with vacuette gel (Greiner) and centrifuged for 10 minutes at
3000 rpm. Plasma was collected and stored at 280uC until use.
The plasma transferrin saturation was measured in Hospital Santo
Anto´nio, using routine procedures, and established to be of 85%.
Isolation of mouse hepatocytes
Hepatocyte isolation was performed by collagenase perfusion, as
previously described [17].
Cell lines
The hepatoma cell line HepG2 was grown in D-MEM
(GibcoBRL) containing 1% of penicillin/streptomycin/amphoter-
icin (PSA) solution and 10% heat-inactivated fetal bovine serum
(FBS).
NTBI uptake
Uptake of non-transferrin- bound iron (NTBI) was assessed
using 55Fe- citrate [18]. 55Fe- citrate stock solutions were prepared
by mixing 55FeCl3 with unlabelled trisodium citrate, at different
Fe:citrate molar ratios. The pH was maintained at 7.4 and
solutions were allowed to rest for 20 minutes before being
diluted 33-fold in uptake medium and added to cells. Specific
activity in the uptake medium was approximately 30 counts.-
min21.pmol21 Fe. Likewise, 14C-labelled ferric citrate was
prepared by mixing 14C-labelled citric acid with unlabeled
FeCl3 at different Fe:citrate molar ratios. The entire procedure
was similar to the one followed for the preparation of 55Fe-
citrate. The specific activity in the uptake medium was
approximately 25 counts.min21.pmol21 citrate. All Fe:citrate
solutions were prepared immediately before use and discarded
after each experiment. Unless otherwise indicated, cells were
depleted of intracellular transferrin by incubation for 1 h in
serum-free/iron-free RPMI, washed and incubated with
RPMI+20% HH plasma+5 mM 55Fe-citrate (as 5 mM
55FeCl3+100 mM citric acid), at 37uC. 5 mM is the typical
NTBI concentration reported in sera from thalassemia major
patients [19] and 100 mM citric acid corresponds to the levels
normally present in human blood plasma [18]. The pH of the
uptake medium was maintained at 7.4. After incubation, cells
were washed 36 with ice-cold buffer [20 mM desferrioxamine
(DFO) in PBS, pH 7.4], lysed with 0.1% NaOH, 0.1% Triton
X-100 and intracellular Fe was measured in a MicroBeta Trilux
b-counter (Perkin Elmer), for 1 minute. No significant changes
in cell viability with iron treatments was observed, using trypan
blue exclusion and maintenance of proliferative potential
following activation with anti-human anti-CD3 and anti-human
anti-CD28 for CD3+, CD4+ and CD8+ T lymphocytes (Figure
S1). To distinguish between intracellular and membrane-bound
Fe and citrate, cells incubated for 30 minutes with varied
Fe:citrate ratios were washed four times with PBS, pH 7.4, at
4uC, and were then incubated with 1 mg/ml of the proteolytic
cocktail Pronase (Sigma) for 30 min, at 4uC. The cell suspension
was centrifuged at 12,000 g for 30 s, and the supernatant
(containing membrane- bound radioactivity) transferred to new
tubes. Cell pellets containing 55Fe radioactivity were solubilized
as described above, while those containing 14C-citrate were
solubilized with 1M NaOH and neutralized with 1N HCl. The
cell lysates and the supernatants were counted for 14C in a
MicroBeta Trilux b-counter, for 5 minutes.
Autometallography
CD3+-cells were sorted from PBMCs using a FITC-conjugated
mouse anti-human CD3 antibody (Abcam), incubated with 5 mM
Fe-citrate (5:100) for up to 3 hours, washed and iron cellular
localization analysed by autometallography coupled with trans-
mission electron microscopy (TEM), as previously described [20].
Briefly, following each period of incubation with Fe-citrate, CD3+
cells were washed with washing buffer and fixed with 2%
glutaraldehyde (in 0.1 M Na- cacodylate+0.1 M sucrose,
pH 7.2). Cells were then submitted to sulfidation with 1%
ammonium sulphide (pH 9.0) in 70% (v/v) ethanol, for 15 min-
utes. After three washes in water, cells were incubated in a colloid-
protected developer containing gum arabic, citrate buffer
(pH 3.8), hydroquinone and silver nitrate, for 25 minutes in the
dark. For transmission electron microscopy, cells were washed in
50 mM sodium cacodylate (pH 7.4), incubated for 24 h in 1%
OsO4 (prepared in 10 mM calcium chloride) and then in 1%
uranyl acetate for 1 h. Following ethanol dehydration and Epon
embedding, ultrathin sections were obtained and analyzed with a
Jeol 1400 (60 kV) microscope equipped with a Orious 1100W
CCD digital camera.
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Speciation plots for ferric citrate species
Speciation plots were developed for Fe-citrate complexes
formed under different ferric ion and citrate concentrations, using
the Hyperquad simulation and speciation (HySS) program [21]
and iron affinity constants previously described [22,23]. The plots
report the species present at equilibrium.
siRNA-mediated silencing
CD4+ and CD8+ cells were transiently transfected with siRNAs
targeting DMT1-IRE, DMT1-non-IRE and ZIP14 mRNAs or with
scrambled siRNAs (all from Eurogentec), using the Amaxa Nucleo-
fector system (Lonza) as previously described [24]. The effect of siRNA
nucleofection on target mRNA levels was quantified by qRT-PCR.
Figure 1. Similar patterns of NTBI uptake by T lymphocytes and hepatocytes. (A) NTBI uptake by human T-lymphocytes. CD4+ and CD8+
human T-lymphocytes were incubated with 5 mM of 55Fe-citrate (5:100) at 37uC and 4uC and intracellular iron quantified at each time-point. Each
point = average (n$3)61SD. (B) NTBI uptake by HepG2 cells. HepG2 cells were incubated with 5 mM of 55Fe-citrate (5:100) for up to 24 hours, at 37uC.
Cell-associated 55Fe levels at each time point were measured. Each point is a mean value (n = 6) 6 SD. Both T-lymphocytes and HepG2 cells are able
to accumulate NTBI presenting a high rate of uptake during the first 30 minutes of incubation (C–D) Specificity of NTBI uptake. CD3+ cells were
incubated with 5 mM of 55Fe-citrate (5:100) for up to 90 min, at 37uC (C) or 4uC (D), and at each time point washed either with PBS (with or without
pronase) or incubated for 15 min with serum-free RPMI with trypsin. Cell-associated 55Fe levels at each time point were measured. Each point is a
mean value (n = 3) 6 SD. The similar results obtained at 37uC together with the differences at 4uC suggest that most of the measured iron is
intracellular. Statistical significance between samples at 37uC and controls at 4uC is indicated by * symbols (*p,0.01).
doi:10.1371/journal.pone.0079870.g001
Figure 2. Kinetics of NTBI uptake in T lymphocytes and hepatocytes. NTBI uptake by human T lymphocytes (A) and HepG2 cells (B). Cells
were incubated with different concentrations of 55Fe-citrate (1 mM, 5 mM, 10 mM, 100 mM, 200 mM and 500 mM) at 37uC and intracellular iron
quantified at various time points (0, 15, 30, 60 and 120 min) (n = 3). The values obtained during the first 30 min of incubation, when the transport
system is not saturated, were used to calculate the rate of uptake for each concentration. CD3+ cells reach saturation at 200 mM of Fe-citrate and
present a maximum rate of 0.4 nmol/min/106 cells, as opposite to HepG2 cells, which do not saturate even at 500 mM and present a faster rate of
uptake (21 nmol/min/106 cells).
doi:10.1371/journal.pone.0079870.g002
Non-Transferrin-Bound Iron Uptake by T Lymphocytes
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e79870
Inhibition of endocytosis - PBMCs and HepG2 cells were washed
twice with MEM Alpha (Invitrogen) medium and pre-incubated
for one hour at 37uC in. Cells were washed again with MEM
Alpha medium and incubated in the presence of sucrose (0.45M)
for 40 min or Dynasore (80 mM) for 30 min. Internalization of
NTBI was measured as the amount of intracellular 55Fe levels
after a 30 min incubation at 37uC with 55Fe-labeled NTBI
(10 mM 55FeCl3, 100 uM sodium citrate) and two washes with
PBS supplemented with DFO (5 mM). Cells were lysed in lysis
buffer (0.1% Triton X-100, 0.1% NaOH) and the radioactive
content in the lysates was measured using a beta counter, as
described above. Internalization of transferrin was measured as
the amount of intracellular 125I-transferrin after 30 min
incubation with 125I-transferrin (2.5 mg/mL) at 37uC. After
the incubation period, cells were washed once with PBS,
followed by two minutes incubation at room temperature in pre-
warmed citrate buffer (150 mM NaCl, 20 mM sodium citrate,
pH 5.0) to strip externally bound Tf and four washes with PBS.
Finally, cells were lysed in lysis buffer (0.1% Triton X-100, 0.1%
NaOH) and the radioactive content in the lysates was measured
with a gamma counter.
Statistical analysis
The results are expressed as mean values +/21 standard
deviation (SD). The existence of correlations between iron
uptake and concentration of Fe-citrate species was assessed by
simple regression analysis, performed with STATGRAPHICS
Centurion XV (Statpoint Technologies). Statistical significance
was set at P,0.01 using Student’s t test in Microsoft Excel
(Microsoft).
Results
Quantification and pattern of NTBI uptake
Both CD4+ and CD8+ human T lymphocytes accumulate
approximately 250 pmol of Fe/106 cells in vitro, when incubated
with 5 mM of 55Fe-citrate (5:100) at 37uC (Figure 1A). The rate of
NTBI uptake is higher during the first 30 minutes of incubation
(6.4 and 7.1 pmol/min./106 cells, respectively for CD4+ - and
CD8+ -lymphocytes), followed by a second component in which
uptake is maintained at a significantly lower rate (461024 and
761022 pmol/min./106 cells, respectively for CD4+- and CD8+-
lymphocytes) until the last time point analyzed (3 hours). A plateau
in intracellular iron levels is reached after approximately
60 minutes. The rate of uptake at 37uC during the initial
30 minutes was significantly higher than at 4uC (0.02 pmol/
min./106 cells).
To compare this pattern with a hepatocyte model, a cell type
that is known to avidly acquire NTBI, we performed the same
experiment in HepG2 cells. Similarly to T lymphocytes, HepG2
cells present an increased rate of NTBI uptake during the first
30 minutes (22.4 pmol/min) (Figure 1B). However, their capacity
to accumulate iron is maintained until the last time point analyzed
(24 hours).
Treatment with pronase and trypsin following incubation with
Fe-citrate did not significantly change cell-associated radioactivity
in CD3+ T lymphocytes (representing total T lymphocytes),
suggesting that the measured Fe is mostly intracellular (Figure 1C).
In contrast, at 4uC most of the NTBI is associated with the plasma
membrane since cell-associated radioactivity was markedly
decreased upon treatment with pronase (Figure 1D).
In addition, we compared the characteristics of the Fe-citrate
transport system between T lymphocytes and hepatocytes by
incubating them with various concentrations of Fe-Citrate
(ranging from 1 mM to 500 mM). We observed that Fe-citrate
uptake in T lymphocytes reaches saturation at 200 mM, with a
Michaelis constant (Km) of 92.6 nmol and maximum velocity
(Vmax) of 0.4 nmol/min./106 cells (Figure 2A). In HepG2 cells
the uptake of Fe-citrate is faster, reaching a rate of 21 nmol/
min./106 cells at 500 mM (Figure 2B). The transport system was
not saturated for the concentrations used, confirming that this
cell type is more effective in taking up NTBI than T
lymphocytes.
To further characterize NTBI uptake by T lymphocytes we
used autometallography coupled with Transmission Electron
Microscopy (TEM) in CD3+-cells exposed to 5 mM Fe-citrate
(5:100) for different time-periods. While in un-treated cells only
a residual small sized silver precipitate was observed, probably
corresponding to non-specific precipitation associated with the
plasma membrane and never intracellularly (Figure 3-I), in cells
incubated with Fe-citrate a clear granule precipitate of variable
size was observed at the cell membrane and in the cytoplasm
after 15 minutes of incubation (Figure 3-II). Cytoplasmic
staining was even stronger at 30 minutes (Figure 3-III), while,
interestingly, after 60 minutes of incubation with Fe and beyond
the large-sized precipitates were almost completely replaced by
smaller granules (Figure 3-IV). These granules, which resemble
the Fe-positive particles observed in these cells with Energy
Dispersive X-ray analysis after 24 h of incubation with Fe-
citrate (Figure S2), possibly reflect the intracellular fragmenta-
tion of the larger iron-containing particles or binding to the
iron-storage protein ferritin.
Altogether, these results show that T lymphocytes are able to
take up and accumulate NTBI in a manner that resembles that of
the HepG2 cell line.
Figure 3. NTBI uptake by T-lymphocytes. Silver sulfide auto-
metallography coupled with Transmission Electron Microscopy was
performed in CD3+ T lymphocytes incubated with 5 mM of Fe-citrate
(5:100) for 15, 30 or 60 minutes. Mock control cells were incubated
without Fe-citrate for 60 minutes. Arrows signal silver grains corre-
sponding to Fe-positive particles that can be visible in the cytoplasm of
cell incubated with Fe-citrate as opposite to mock control cells in which
it is only associated with the plasma membrane. Highest intensity was
obtained at 30 min incubation. C = cytoplasm; PM=plasma membrane;
N =nucleus. Bars = 200 nm.
doi:10.1371/journal.pone.0079870.g003
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Ferric citrate species taken up by hepatocytes and T
lymphocytes
Having established that T lymphocytes and hepatocytes take up
NTBI with similar patterns, we analyzed the uptake by both cell
types in conditions favoring the presence of distinct Fe-citrate
species. Although it is commonly accepted that Fe-citrate is one of
the most relevant NTBI forms in iron overload disorders, nothing
is known regarding the selectivity for particular Fe-citrate species
by cells. Taking advantage of the recent development of a
speciation model for Fe-citrate [22], we investigated iron uptake
by hepatocytes and T lymphocytes in the presence of various
Fe:citrate ratios, for which the model predicts the formation of
distinct Fe-citrate species. In the presence of 100 mM citrate,
increase of Fe concentration from 0.1 to 100 mM is predicted to
induce a shift from the FeCit2 species to the oligomeric Fe3Cit3,
this latter species being essentially the only one present for iron
concentrations equal or above 100 mM (Figure 4A and Table 1).
When primary mouse hepatocytes, HepG2 cells and CD3+
lymphocytes were incubated with an equal volume of each of
these Fe-citrate solutions, a dose-dependent increase in Fe uptake
was observed up to 100 mM Fe for all cell types (Figure 4B), with a
strong positive correlation observed between NTBI uptake and
[Fe3Cit3] (Figure 4C). In contrast, when the three cell types were
exposed to media predicted to contain increasing concentrations of
Fe3Cit3 and FeCit2 (Figure 5A and Table 2), Fe uptake by
hepatocytes and T cells increased only while [Fe3Cit3] was
increasing and stabilized or was inhibited when [Fe3Cit3]
remained stable (Figure 5A–B). The hepatoma cell line HepG2
showed a slightly different pattern of Fe uptake than hepatocytes
and T lymphocytes for a particular condition in which [Fe3Cit3]
remained constant and [FeCit2] increased almost 3-fold (10 mM
Fe: 200 mM citrate). In this condition, HepG2 cells continued to
increase Fe uptake, suggesting that these tumor cells may have a
higher affinity for FeCit2 than non-transformed cells. Finally, a
Figure 4. Fe uptake by T lymphocytes and hepatocytes correlates with [Fe3Cit3]. (A) Speciation plots for Fe-citrate species were calculated
for Fe:citrate ratios from 1:100–200:100 using the Hyperquad simulation and speciation (HySS) program. Predicted relative abundance (%) of the two
most common Fe-citrate species, at pH 7.4, is marked by a blue vertical line and a red (Fe3Cit3) or blue (FeCit2) dot. (B) Fe uptake by T lymphocytes
and hepatocytes incubated with different iron:citrate ratios increases with the relative abundance of Fe3Cit3. Experiments were performed at least
three times with three replicates per experiment. Each point represents the mean (n = 3) 61SD. (C) Regression analysis showing a significant
correlation between Fe uptake by CD3+ (left) and HepG2 (right) cells with predicted [Fe3Cit3] concentration at pH 7.4.
doi:10.1371/journal.pone.0079870.g004
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predicted 10-fold increase in [FeCit2] (with constant [Fe3Cit3];
Table 2) significantly inhibited Fe uptake by the three populations,
with no correlation found between [FeCit2] and NTBI uptake by
HepG2 and T lymphocytes (P=0.15 and P=0.14, respectively for
CD3+ cells and HepG2) (Figure 5C). No association was found
between the concentration of any other Fe-citrate species
predicted to be present and Fe uptake (data not shown).
To test if the observed differences in the uptake of distinct Fe-
citrate species could be due to differences in the binding of Fe-
citrate to the cell membrane, we compared the patterns of
citrate binding and internalization for FeCit2 and Fe3Cit3 in
each cell type. Results show that the uptake (Figure 6A, C) and
the binding of citrate to the cell membrane (Figure 6B, D) by the
three cell types follows the same pattern observed for the uptake
of 55Fe from Fe-citrate in each condition, suggesting that
Fe3Cit3, rather than FeCit2, is preferentially bound to the cell
membrane. Thus, differences in Fe uptake observed between
each experimental condition cannot be attributed to a prefer-
ential internalization of Fe from membrane-bound Fe-citrate. It
is important to state that iron precipitation, namely of ferric
hydroxide, was controlled by measuring the absorbance of the
ferric citrate solutions in the 280–500 nm range, with no
significant decrease in the absorbance values observed for any of
the solutions.
Mechanism of NTBI uptake
Previous results from other groups (see Brissot et al. [6] for a
review) have suggested that the uptake of NTBI requires specific
transporters. The present evidence that NTBI uptake is essentially
restricted to the Fe3Cit3 species corroborates that notion. Since
DMT1 and ZIP14 are the two proteins most consistently
implicated in the cellular uptake of non-heme NTBI [25], we
analyzed the impact of these 2 molecules in the transport of
NTBI in T lymphocytes. We found here that protein and
mRNA basal expression of DMT1 and ZIP14 is either
undetectable or very low in T lymphocytes and that both
mRNAs are unresponsive to incubation with Fe-citrate or DFO
(data not shown). Moreover, siRNA-mediated silencing of the
two mRNAs to 20–40% of its basal levels had no significant
effect on the NTBI uptake by CD4+ and CD8+ cells (Figure 7),
ruling out a major contribution of these two proteins to NTBI
uptake in these cells. To test whether endocytosis is a significant
pathway for NTBI uptake by circulating blood cells, we
incubated Peripheral Blood Mononuclear Cells (PBMCs) with
10 mM Fe-Citrate (1.12 mM Fe3Cit3) in the presence or absence
of different endocytosis inhibitors. To assess the reach of the
results, the experiments were repeated in the HepG2 cell line, a
model for the hepatocyte, which accumulates the highest NTBI
levels. Inhibition of the clathrin-dependent pathway using
hypertonic sucrose solutions did not affect NTBI uptake by
either cell type, while significantly reducing 125I-transferrin
internalization in HepG2 cells (Figure 8A, C). Interestingly,
incubation with 80 mM Dynasore, a potent inhibitor of dynamin
GTPase activity [26], induced a marked increase in NTBI
uptake (aprox. 1286 and 406, respectively for PBMCs and
HepG2; Figure 8B), while significantly decreasing transferrin
uptake (Figure 8D). Although the present results do not exclude
the use of alternative endocytosis pathways for NTBI uptake by
PBMCs and hepatocytes, they argue against the use of the
clathrin-dependent pathway. A summary of the putative NTBI
transport systems in T lymphocytes and hepatocytes and
addressed in this study, as well as those previously described
in the literature, is represented on Figure 9.
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Discussion
Despite the importance of NTBI in the pathophysiology of iron
overload, little is still known about its chemical composition as well
as about the uptake mechanisms and selectivity for distinct NTBI
presentations by different cell types. Several potential iron-binding
ligands are present in plasma, including citrate, acetate and
albumin. Albumin, the most abundant blood plasma protein [27],
has been shown to bind iron both in the presence of citrate, as a
ternary complex, or in its absence [28]. Nevertheless, May et al.
[29], based on the relative concentrations of potential ligands,
predicted the dominant iron species in plasma to be ferric-citrate,
the NTBI form used in the present study. By using a culture
medium containing 20% plasma from an iron-overloaded patient,
we tried to reproduce the conditions to which both hepatocytes
and T lymphocytes are exposed during iron overload. Using this
experimental setup we observed a strong and exclusive association
between Fe uptake and the predicted presence of the Fe3Cit3
oligomer in solution, in contrast with the lack of association with
FeCit2 or with any other ferric citrate species. Admittedly, there
are differences in the media composition used for the development
of the speciation models (salt-buffered aqueous solution) and for
the Fe uptake assays (RPMI supplemented with 20% HH plasma).
One could argue that the model predictions for a simple aqueous
solution may not hold for a complex medium in which several iron
binding molecules not considered in the model are present.
However, significant changes in the predicted speciation between
the aqueous solution and the uptake medium would only be
expected if there is competition for Fe by those ligands. Under our
conditions transferrin will not significantly compete with citrate,
since it is 85% saturated. Similarly, acetates, pyruvates and
phosphates will not compete with citrate for Fe when the citrate
concentration is $100 mM [29], as it is the case in our
experimental conditions as well as in human plasma. Finally,
albumin has been described to efficiently bind iron [28] but its
ability to significantly modify citrate-bound iron is dependent on
its glycation and oxidation [30]. Healthy individuals have
approximately only 1% of their serum albumin glycated, with
this value increasing to 10% in diabetic patients [27]. No changes
relatively to the 1% baseline have been described in iron-
overloaded individuals, suggesting that, at least on the absence
of increased glucose levels, glycated albumin will not significantly
compete for iron with citrate. Albumin oxidation, on the other
hand, could have a relevant effect, in face of the pro-oxidant
conditions expected to arise during iron overload. Previous studies
have shown that fully oxidized albumin does not show increased
iron binding capacities up to 5 mM of iron, but a 2.6- fold increase
was observed for 10 mM of Fe [30]. Thus, in pro-oxidant
conditions albumin may show an increased capacity to modify
citrate-bound concentrations, although we predict that this will
only be significant for very high NTBI concentrations and
extensive albumin oxidation.
Figure 5. Fe uptake by T lymphocytes and hepatocytes does not correlate with [FeCit2]. (A) Speciation plots for Fe-citrate species,
calculated for increasing Fe-citrate concentrations maintaining a constant Fe:citrate ratio of 1:20 using the Hyperquad simulation and speciation
(HySS) program. Predicted relative abundance (%) of the two most common Fe-Cit species at pH 7.4 is marked by a blue vertical line and a red
(Fe3Cit3) or blue (FeCit2) dot. (B) Fe uptake by CD3
+ lymphocytes and HepG2 cells in the presence of increasing Fe-citrate concentrations, maintaining
a constant Fe:citrate ratio of 1:20 (same conditions as in panel A). Experiments were performed at least three times with three replicates per
experiment. Each point represents the mean (n = 3) 61SD. (C) Regression analysis showing no significant correlation between Fe uptake by CD3+
(left) and HepG2 (right) cells with predicted [FeCit2] concentration at pH 7.4.
doi:10.1371/journal.pone.0079870.g005
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The liver is one of the first and most affected organs in iron
overload diseases such as beta-thalassemia and hereditary hemo-
chromatosis. The uptake of NTBI by hepatocytes was previously
described and is considered to act as a reservoir to protect other
tissues from iron-mediated toxicity. The role of T lymphocytes in
the uptake of NTBI has been less clear. Although the present study
does not prove a role for T lymphocytes in protection from NTBI
toxicity, the unequivocal demonstration of the uptake and
accumulation of NTBI by T lymphocytes, together with previous
results from our group showing that there is a negative correlation
between the number of T lymphocytes and the severity of iron
overload in HH patients [15,16], leads us to hypothesize that these
cells could act as buffers to protect other tissues from iron-
mediated toxicity, confirming the postulate put forward by de
Sousa and co-workers on the first demonstration of H-ferritin
synthesis by human T and not B lymphocytes [31]. This early
observation gains now new significance in view of recent work in
conditional deletion of ferritin H in mice [32].
The mechanism for the cellular uptake of NTBI is still elusive.
To address this question we analyzed the putative involvement of
DMT1 and ZIP14 in the uptake of Fe-citrate by T lymphocytes.
These two proteins have been previously suggested to have a role
in the uptake of non-heme NTBI by hepatocytes [25]. In the case
of Tlymphocytes, however, we found that the silencing of these
Table 2. Calculated concentrations of Fe-citrate (FeCit) species for increasing doses of Fe and a constant Fe:Citrate ratio of 1:20.
0,1 mM Fe: 2 mM Cit 1 mM Fe: 20 mM Cit 5 mM Fe: 100 mM Cit 10 mM Fe: 200 mM Cit 100 mM Fe: 2000 mM Cit
Fe3Cit3 (mM) 6.21610
27 3.9161022 2.461021 3.1561021 4.2661021
FeCit2 (mM) 1.19610
23 4.4961021 3.95 8.61 94.7
FeCit2H (mM) 5.02610
25 1.9061022 1.6761021 3.6361021 3.99
FeCitH (mM) 5.9061026 2.3561024 4.3061024 4.7161024 5.2161025
FeCit2H2 (mM) 1.56610
27 5.9061025 5.1961024 1.1361023 1.2461022
Fe free (mM) 2.16610210 9.04610210 3.44610210 1.89610210 2.11610211
Cit free (mM) 9.9561028 9.4461027 4.5361026 9.0261026 8.9761025
H free (mM) 3.9861022 3.9861022 3.9861022 3.9861022 3.9861022
doi:10.1371/journal.pone.0079870.t002
Figure 6. Uptake of citrate reflects the cell membrane binding capacity of each Fe-citrate species. Cells were incubated for 30 minutes
with varied Fe:citrate ratios and then treated with pronase. 14C-citrate radioactivity was measured in the cell lysates (intracellular fraction; A and C)
and in the supernatants (membrane fraction; B and D). (A–B) Citrate uptake (A) and cell membrane-binding (B) by HepG2, hepatocytes and CD3+
lymphocytes in conditions of predicted increase of Fe3Cit3. (C–D) Citrate uptake (C) and cell membrane-binding (D) in the presence of increasing Fe-
citrate concentrations, maintaining a constant Fe:citrate ratio of 1:20. Each point represents the mean (n = 3) 61SD.
doi:10.1371/journal.pone.0079870.g006
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two proteins does not have a major impact on Fe-citrate uptake,
which suggests the involvement of a different, unidentified
transporter that most likely favors the transport of ferric iron,
differing from DMT-1 and ZIP14 which preferentially transport
its ferrous form [33,34]. A recent study has suggested that
endocytic pathways mediate the uptake of NTBI by a human
macrophage cell line and cardiac myoblasts/myocytes [35]. Using
two different endocytosis inhibitors we demonstrated their
effectiveness in inhibiting transferrin-bound-iron uptake, but not
affecting NTBI internalization. The most likely explanation resides
in the NTBI presentation used. The authors above used Fe-
albumin as a source of NTBI and argue that this may be the main
NTBI physiologically available to the cells. Our data with T
lymphocytes and HepG2 cells show that, in our experimental
conditions, albumin has a mild inhibitory effect on NTBI uptake
(1162%, data not shown), suggesting the inability of these cells to
efficiently take up NTBI in this presentation. Although the
existence of cell-specific differences has to be considered, data
from previous studies showing, namely, that the rate of NTBI
uptake is up to 3006 faster as that from Fe-TF [36] and that, in
plasma from thalassemic patients, NTBI is unlikely to be bound to
albumin to a significant extent [37], support our conclusion that,
at least for the cell types analyzed, endocytosis is not significantly
involved in NTBI uptake. Previous studies also suggest that Fe-
citrate uptake occurs by a passive, carrier-mediated process
[2,38,39], with the identity of the carrier still unknown. The most
favored hypothesis is that upon binding to its receptor, Fe-citrate is
dissociated and Fe and citrate are taken up independently by cells
[40,41], with the concomitant reduction of ferric iron in the
process. Our results reveal a remarkably similar pattern between
Fe and citrate uptake, although a trend for a higher rate of
citrate uptake over Fe was observed, supporting the hypothesis
that different mechanisms control the uptake of the two
components. The present results also show that the differences
in Fe uptake in each experimental condition and the high
correlation between Fe3Cit3 and Fe uptake are not due to a
preferential uptake of membrane-bound Fe in particular
conditions but instead may reflect a high specificity of a
putative receptor for the oligomeric Fe-citrate species. We
anticipate that this finding may be instrumental in the search for
the elusive Fe-citrate transporter since it represents the
identification of the ligand to which the transporter may
respond, either at the level of transcription, translation or other
form of modification. The high correlation between the
presence of the oligomer Fe3Cit3 and Fe uptake may be
surprising, as donation of Fe by smaller sized mononuclear Fe-
citrate species might be expected to be more facile, particularly
if the uptake involves a channel transporter. However,
predictions from models and from kinetics of NTBI chelation
by DFO and deferiprone suggested that the dominant species
under relevant concentrations of citrate are likely to be
oligomeric forms, with a molecular mass around 3.5 kDa
[22,42]. It seems thus reasonable to expect that, throughout
evolution, cells have specialized in sensing and internalizing this
particular species. Nevertheless, it is conceivable that particular
tissues and cell types may be equipped with different cellular
NTBI uptake systems, which would enable the discrimination
between distinct NTBI species and could explain the different
patterns of organ iron-loading observed in the various iron
overload syndromes [43]. Particularly interesting would be to
extend the present analysis to cardiomyocytes, a cell type in
which NTBI accumulation has a particularly adverse effect
[44,45] and for which the involvement of specific NTBI
transporters have been suggested [46]. Finally, the demonstra-
tion that Fe3Cit3 represents an important component of the
NTBI taken up by hepatocytes and T lymphocytes could be
used as a tool for optimization of chelator properties and of
chelation regimens presently in use.
Supporting Information
Figure S1 Effect of NTBI uptake on T lymphocyte
proliferation. CD3+ lymphocytes were incubated with RPMI
(left panel) or RPMI+ aCD3+ aCD28 (right panel), in the absence
(Mock) or presence of Fe-citrate (5 or 50 mM) and cell number
determined by direct counting using a Neubauer chamber every
24 hours. Figure represents the average61SD of two independent
experiments; *P=0.003 between Fe-citrate-treated samples and
Mock (two-way ANOVA).
(TIF)
Figure S2 Intracellular NTBI detection in T lympho-
cytes. CD3+ cells were incubated with 5 mM of Fe-citrate (5:100)
or in Fe-Citrate-free medium (Mock) for 24 hours, followed by
elemental analysis using Energy Dispersive X-ray spectroscopy.
Fe-specific signals (white dots) were observed in the cytoplasm
(more) and nucleus (less) of NTBI-treated (I) and not in mock cells
(II), showing that this cell type is able to take up Fe-citrate.
Bars = 200 nm.
(TIF)
Figure 7. Involvement of NTBI transporters in Ferric citrate
uptake by T lymphocytes. mRNA levels (A; qRT-PCR) and
corresponding NTBI uptake (B) by CD4+ and CD8+ T lymphocytes
following nucleofection with siRNAs specific for ZIP14, DMT1-IRE and
DMT1-nIRE, with scrambled siRNAs (siNeg) or with no DNA as controls.
Each column represents the mean value (n = 3) 6 SD. Statistical
significance between samples (grey columns) and controls (white
columns) is indicated by * symbols (*p,0.01). No differences in
Fe:citrate uptake were observed after silencing DMT1 or ZIP14.
doi:10.1371/journal.pone.0079870.g007
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Figure 8. Involvement of clathrin-mediated endocytosis in NTBI uptake by PBMCs and HepG2 cells. (A–B) 55Fe uptake by PBMCs and
HepG2 cells in the presence of 0.45M of sucrose (A) or 80 mM of Dynasore (B) to inhibit clathrin-mediated endocytosis, after incubation with 5 mM of
55Fe-citrate (5:100) at 37uC (C–D) 125I-Transferrin internalization in the presence of 0.45M of sucrose (C) or 80 mM of Dynasore (D). Each bar represents
a mean value (n = 3)6 SD. Statistical significance is indicated by * symbols (*p,0.01). The inhibition of these pathways did not prevent the uptake of
NTBI in both PBMCs and HepG2 cells but transferrin internalization was decreased.
doi:10.1371/journal.pone.0079870.g008
Figure 9. Iron uptake by T lymphocytes and hepatocytes. Transferrin-bound iron is internalized by TFR1-mediated endocytosis in hepatocytes [47]
and T-lymphocytes [48]. Non-transferrin-bound iron (NTBI) is taken up by hepatocytes via Zrt- and Irt-like Protein 14 (ZIP14, Slc39A14; after ferric reductase-
mediated reduction of Fe3+ to Fe2+) [49,50]. Divalent metal transporter 1 (DMT1) was the first described NTBI (Fe2+) transporter [51], although recent data
suggests it may not be important for the iron loading of the hepatocyte [52]. We hypothesize that ZIP14 and DMT1 are not involved in the uptake of ferric
citrate by T lymphocytes (red6symbols). Clathrin-mediated endocytosis of ferric citrate does not occur in hepatocytes and T lymphocytes (red6symbols). T
lymphocytes and hepatocytes selectively take up the oligomer Fe3Cit3, which suggests the existence of a specific transporter (green symbols).
doi:10.1371/journal.pone.0079870.g009
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File S1 Supporting methods. Experimental procedures used
to analyze T lymphocyte activation and proliferation; description
of the Energy Dispersive X-ray analysis technique performed for
elemental mapping of iron-loaded lymphocytes.
(DOCX)
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